Latest Conference Articles

Achieving a Personalized Digital Control Arm for Preclinical Drug Evaluation

November 13th 2025

At AAPS PharmSci 360 2025, Elly Zhou says digital twins helped forecast the effects of drugs on human drugs via a digital control arm.

How 3D-Printed Tablets Can Optimize IgA Nephropathy Treatment

November 12th 2025

At AAPS PharmSci 360, Xialing Li, PhD, says 3D-printed budesonide tablets achieve precise, delayed delivery to the ileum for IgA nephropathy, lowering in vivo variability.

AI-Powered Digital Twins Achieve High Accuracy in Human Lung Function Forecasting

November 11th 2025

At AAPS PharmSci 360, Xuanzi Zhou says digital twins accurately predict ex vivo lung function, revealing therapeutic effects missed by conventional preclinical drug testing.

Defining An Agitation Model for Early-Stage, High Concentration Biologics Formulation Development

November 11th 2025

AAPS

Siddhant Sojitra, Alexion, defines in an AAPS PharmSci 360 2025 presentation an agitation model to reliably test stability for early-stage biologics.

Using A Streamlined Workflow to Identify Particulates in Biologic Drugs

November 11th 2025

In a poster presentation at AAPS PharmSci 360, Eda Fenercioglu, a scientist at Pfizer, outlines a streamline workflow for identifying and mitigating visible particles in biologic drugs.

AAPS PharmSci 360 2025: Instrumentation Innovation for Bioanalysis

November 11th 2025

Pharmaceutical Technology® spoke with Steve Lowes, senior director of Scientific Affairs at IQVIA Laboratories, ahead of AAPS PharmSci 360 to discuss some of the unique instruments used to conduct bioanalysis.

Why Context Matters in Validating Biomarker Assays for Bioanalysis

November 10th 2025

Pharmaceutical Technology® spoke with Steve Lowes, senior director of Scientific Affairs at IQVIA Laboratories, ahead of AAPS PharmSci 360 to discuss method validation of biomarker bioanalysis.

Using AI and Molecular Dynamics to Overcome the Poor Solubility Challenge

November 10th 2025

In a poster presentation at AAPS PharmSci 360, by Dineli Ranathunga, PhD, indicates that AI/ML in-silico modeling can accelerate poorly soluble drug development.

Why Investment Strategies Matter for Advancing Pharmaceutical Technologies

November 7th 2025

PharmSci 360 will spotlight the economics behind AI, scale-up, and advanced modalities, addressing cost barriers that influence future drug manufacturing.

AAPS PharmSci 360: Enhancing Bioanalysis with AI and Other Technologies

November 7th 2025

Pharmaceutical Technology® spoke with Dr. Mark Arnold, owner and principal, Bioanalytical Solution Integration, ahead of AAPS PharmSci 360 to find out how bioanalysis enhances bio/pharmaceutical drug development.